Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO

Business Wire July 20, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  July 20, 2017

28 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  July 20, 2017

Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide

Benzinga.com  July 19, 2017

Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates

Benzinga.com  July 19, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  July 19, 2017

NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date

Business Wire July 18, 2017

Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults

Business Wire June 30, 2017

Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference

Business Wire June 9, 2017

Marcum Conference To Connect Public, Private Micro-Caps With Critical Investors

Benzinga.com  May 18, 2017

Aeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting

Business Wire May 9, 2017

Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results

Business Wire May 8, 2017

Aeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017

Business Wire May 2, 2017

Mid-Day Market Update: Crude Oil Down 1.5%; Neurotrope Shares Plummet

Benzinga.com  May 1, 2017

Mid-Morning Market Update: Markets Mostly Higher; DISH Network Profit Tops Estimates

Benzinga.com  May 1, 2017

IIROC Trade Resumption - AEZS

Canada NewsWire May 1, 2017

CORRECTION FROM SOURCE: IIROC Trade Resumption - Aeterna Zentaris Inc.

Newsfile May 1, 2017

IIROC Trading Halt - AEZS

Canada NewsWire May 1, 2017

IIROC Trade Halt - Aeterna Zentaris Inc.

Newsfile May 1, 2017

Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint

Business Wire May 1, 2017